PTPN11 and colorectal carcinoma: Given that SHP2 allosteric inhibitor TNO155, which is developed from SHP099, has been employed in clinical trials of KRASmutant solid tumors (59), we investigated to determine whether SHP2 inhibition led to a better treatment outcome in MSS CRC.